Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Nov 23;12(12):1653.
doi: 10.3390/antibiotics12121653.

Intravenous Fosfomycin for Systemic Multidrug-Resistant Pseudomonas aeruginosa Infections

Giuseppe Pipitone  1 , Stefano Di Bella  2 , Alberto Enrico Maraolo  3 , Guido Granata  4 , Milo Gatti  5   6 , Luigi Principe  7 , Alessandro Russo  8 , Andrea Gizzi  1   9 , Rita Pallone  10 , Antonio Cascio  9 , Chiara Iaria  1
Affiliations
Review

Intravenous Fosfomycin for Systemic Multidrug-Resistant Pseudomonas aeruginosa Infections

Giuseppe Pipitone et al. Antibiotics (Basel). .

Abstract

Human Pseudomonas infections have high morbidity and mortality rates. Pseudomonas bacteria can cause sepsis or septic shock; they produce biofilm and commonly exhibit a multidrug-resistant phenotype. The choice of antimicrobial therapy in many cases is challenging, and deep knowledge of clinical, microbiological, and pharmacological issues is required. Intravenous fosfomycin is being repurposed in a combination given its favorable pharmacokinetic/pharmacodynamic properties (a small molecule with favorable kinetic both in bloodstream infection and in deep-seated infections), antibiofilm activity, and its interesting synergistic effects with other antimicrobials. Recent literature on epidemiological, microbiological, pharmacological, and clinical data on intravenous fosfomycin therapy against Pseudomonas is herein reviewed and discussed.

Keywords: Pseudomonas aeruginosa; difficult-to-treat P. aeruginosa; fosfomycin; multidrug resistance.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. Tamma P.D., Aitken S.L., Bonomo R.A., Mathers A.J., van Duin D., Clancy C.J. Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections. Clin. Infect. Dis. 2023;2023:ciad428. doi: 10.1093/cid/ciad428. - DOI - PubMed
    1. Antonello R.M., Principe L., Maraolo A.E., Viaggi V., Pol R., Fabbiani M., Montagnani F., Lovecchio A., Luzzati R., Di Bella S. Fosfomycin as Partner Drug for Systemic Infection Management. A Systematic Review of Its Synergistic Properties from In Vitro and In Vivo Studies. Antibiotics. 2020;9:500. doi: 10.3390/antibiotics9080500. - DOI - PMC - PubMed
    1. Avery L.M., Sutherland C.A., Nicolau D.P. Prevalence of in vitro synergistic antibiotic interaction between fosfomycin and nonsusceptible antimicrobials in carbapenem-resistant Pseudomonas aeruginosa. J. Med. Microbiol. 2019;68:893–897. doi: 10.1099/jmm.0.000984. - DOI - PubMed
    1. Memar M.Y., Adibkia K., Farajnia S., Samadi Kafil H., Khalili Y., Azargun R., Ghotaslou R. In-vitro Effect of Imipenem, Fosfomycin, Colistin, and Gentamicin Combination against Carbapenem-resistant and Biofilm-forming Pseudomonas aeruginosa Isolated from Burn Patients. Iran J. Pharm. Res. 2021;20:286–296. doi: 10.22037/ijpr.2020.111824.13380. - DOI - PMC - PubMed
    1. Testing E.C.o.A.S. Breakpoint Tables for Interpretation of MICs and Zone Diameters. [(accessed on 2 October 2023)]. Available online: https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_....

LinkOut - more resources